INTERCEPT Blood System for Platelets



Viruses

The INTERCEPT Blood System for platelets has been shown to inactivate a variety of viruses. Of viruses tested to date, only HAV and PPV were resistant to inactivation. The results of these studies are summarized in Table 1.

Table 1. Inactivation Claims - Viruses

Viruses Tested Using
the INTERCEPT Blood System
Extent of Inactivation* (log10 reduction)
Platelets in plasma/Additive solution
Platelets in plasma
Enveloped Viruses
HIV-1 (cell-associated)***
>6.1
>6.7
HIV-1 (cell-free)
>6.2
≥4.7
Clinical isolate of HIV-1
>3.4
-
Clinical isolate of HIV-2
>2.5
-
Latent proviral HIV-1
Inactivated to the limit of detection
-
HBV (strain MS-2)
>5.5
>4.5
HCV (strain Hutchison)
>4.5
>4.5
HTLV-I (Human T-cell Lymphotropic Virus)***
4.7**
≥4.5
HTLV-II (Human T-cell Lymphotropic Virus)***
5.1**
>5.7
Cell-associated Cytomegalovirus (CMV)***
>5.9
-
Bovine Viral Diarrhea Virus (BVDV, model virus for human HCV)
>6.0
≥5.4
Duck Hepatitis B Virus (DHBV, model virus for human HBV)
>6.2
4.4 to 4.5
PRV (Pseudorabies virus, model for CMV)
-
≥4.7
West Nile virus
>6.0
≥6.8
SARS-CoV (Human Corona virus)
-
≥5.5
Chikungunya virus
>6.4
≥7.6
Influenza A H5N1 virus (Avian Influenza)
>5.9
>5.7
Non-Enveloped Viruses 
Bluetongue Virus, type 11
>5.0
5.1
Calicivirus
1.7 to 2.4
-
Human Adenovirus-5
>5.9
≥6.9
Parvo (Parvovirus B19)
-
1.8
* “>” refers to inactivation below the limit of detection of the assay. In some cases assays have a very small dynamic range due to limits on attainable virus titers.
** inherent low-level background in non-infected indicator cells precludes “>” of HTLV
*** intracellular
“-” means not tested


Previous PagePlatelet Technical Data Sheet Page 3 of 7Next Page

Untitled Document